Therapeutic Drug Monitoring for Evaluation of the Efficacy and Safety of Vancomycin in Patients with Orthopaedic Infections

Therapeutic Drug Monitoring for Evaluation of the Efficacy and Safety of Vancomycin in Patients with Orthopaedic Infections

Vancomycin is a drug of choice for the infections caused by methicillin-resistant strains of staphylococci. Its use requires individualised dosing and renal function monitoring.The aim of the study was to evaluate, using therapeutic drug monitoring (TDM), the frequency of reaching target trough seru...

Full description

Bibliographic Details
Main Authors:	O. S. Tufanova, A. R. Kasimova, S. A. Bozhkova
Format:	Article
Language:	Russian
Published:	Ministry of Health of the Russian Federation, Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» 2022-07-01
Series:	Безопасность и риск фармакотерапии
Subjects:	vancomycin nephrotoxicity therapeutic drug monitoring trough serum concentration drug-induced renal disorder
Online Access:	https://www.risksafety.ru/jour/article/view/276

Similar Items

Is It Still Beneficial to Monitor the Trough Concentration of Vancomycin? A Quantitative Meta-Analysis of Nephrotoxicity and Efficacy
by: Wanqiu Yang, et al.
Published: (2024-05-01)

Early Vancomycin Concentrations and the Applications of a Pharmacokinetic Extrapolation Method to Recognize Sub-Therapeutic Outcomes
by: Oscar Santalo, et al.
Published: (2016-11-01)

Extremely high levels of vancomycin can cause severe renal toxicity
by: Barceló-Vidal J, et al.
Published: (2018-07-01)

Therapeutic drug monitoring of vancomycin in patients with infectious complications in traumatology and orthopedics
by: Borisov A.M., et al.
Published: (2020-03-01)

Vancomycin dosing design method considering risk factors for nephrotoxicity
by: Yoshihiko Matsuki, et al.
Published: (2025-02-01)

Vancomycin Therapeutic Drug Monitoring (TDM) and Its Association with Clinical Outcomes: A Retrospective Cohort
by: Juhaina Salim Al-Maqbali, et al.
Published: (2022-05-01)

Outcomes and Nephrotoxicity Associated with Vancomycin Treatment in Patients 80 Years and Older
by: Wang Y, et al.
Published: (2021-06-01)

Determination of a vancomycin nephrotoxicity threshold and assessment of target attainment in hematology patients
by: Sherilyn Wong, et al.
Published: (2024-08-01)

Is it time to recommend AUC-based vancomycin therapeutic drug monitoring only? A cross-sectional survey in China
by: Jieqiong Liu, et al.
Published: (2024-07-01)

Evaluation of the variability and safety of serum trough concentrations of vancomycin in patients admitted to the intensive care unit
by: Xiaodan Qian, et al.
Published: (2017-07-01)

Evaluation of body weight-based vancomycin therapy and the incidence of nephrotoxicity: a retrospective study in the northwest of China
by: Mo-Han Dong, et al.
Published: (2015-08-01)

Relationship between nephrotoxicity and area under the concentration–time curve of vancomycin in critically ill patients: a multicenter retrospective study
by: Tomoyuki Ishigo, et al.
Published: (2024-07-01)

Therapeutic drug monitoring of vancomycin in an obese patient with renal insufficiency
by: Said Abuhasna, et al.
Published: (2011-01-01)

Clinical Application Value of Pharmacokinetic Parameters of Vancomycin in Children Treated in the Pediatric Intensive Care Unit
by: Bo Zhou, et al.
Published: (2022-06-01)

Is vancomycin monitoring of real value in pediatric cancer patients?
by: Mohamed S. Imam, et al.
Published: (2018-03-01)

Effect of First Trough Vancomycin Concentration on the Occurrence of AKI in Critically Ill Patients: A Retrospective Study of the MIMIC-IV Database
by: Longzhu Li, et al.
Published: (2022-04-01)

The impact of vancomycin trough concentrations on outcomes in non-deep seated infections: a retrospective cohort study
by: Michael Wan, et al.
Published: (2018-07-01)

Therapeutic Drug Monitoring of Vancomycin Concentrations for the Management of Bone and Joint Infections: An Urgent Need
by: Laura Rio-No, et al.
Published: (2023-02-01)

The Thirty-Day Mortality Rate and Nephrotoxicity Associated With Trough Serum Vancomycin Concentrations During Treatment of Enterococcal Infections: A Propensity Score Matching Analysis
by: Wasan Katip, et al.
Published: (2022-01-01)

The monitoring of vancomycin: a systematic review and meta-analyses of area under the concentration-time curve-guided dosing and trough-guided dosing
by: Moeko Tsutsuura, et al.
Published: (2021-02-01)

Factors affecting a variability of serum vancomycin concentrations in clinical practice
by: Kostitsyna M.A., et al.
Published: (2017-08-01)

Therapeutic Monitoring of Vancomycin Implemented by Eremomycin ELISA
by: Inna A. Galvidis, et al.
Published: (2024-11-01)

Vancomycin-induced nephrotoxicity with unusual high serum trough level in a critically ill young patient
by: Yi Xin Cheng, et al.
Published: (2016-01-01)

Reply to Mitsuboshi, “Enhancing result reliability by addressing potential confounding factors”
by: Tomoyuki Ishigo, et al.
Published: (2025-03-01)

Factors influencing vancomycin trough concentration in burn patients: a single center retrospective study
by: Yan Shi, et al.
Published: (2024-12-01)

Comparison of vancomycin serum levels prior to and post therapeutic drug monitoring in patients admitted to hospital
by: Kaveh Eslami, et al.
Published: (2021-09-01)

Linezolid dose adjustment according to therapeutic drug monitoring helps reach the goal concentration in severe patients, and the oldest seniors benefit more
by: Ying Xu, et al.
Published: (2023-11-01)

Prediction of vancomycin initial dosage using artificial intelligence models applying ensemble strategy
by: Wen-Hsien Ho, et al.
Published: (2023-03-01)

Candidates for area under the concentration–time curve (AUC)-guided dosing and risk reduction based on analyses of risk factors associated with nephrotoxicity in vancomycin-treated patients
by: Naoto Hashimoto, et al.
Published: (2021-12-01)

What Is the Best Vancomycin Therapeutic Drug Monitoring Parameter to Assess Efficacy? A Critical Review of Experimental Data and Assessment of the Need for Individual Patient Minimum Inhibitory Concentration Value
by: Bruce R. Dalton
Published: (2023-02-01)

Vancomycin treatment: analysis of efficacy and safety
by: Brigita Mavsar-Najdenov, et al.
Published: (2007-11-01)

Age-Related Differences in Vancomycin-Associated Nephrotoxicity and Efficacy in Methicillin-Resistant <i>Staphylococcus aureus</i> Infection: A Comparative Study between Elderly and Adult Patients
by: Lin Xi, et al.
Published: (2024-04-01)

Vancomycin in ICU Patients with Gram-Positive Infections: Initial Trough Levels and Mortality
by: Alshehri N, et al.
Published: (2020-10-01)

Experience of Using Therapeutic Drug Monitoring to Control the Safety of Vancomycin in Intensive Care Unit Patients with Sepsis
by: A. B. Prokofiev, et al.
Published: (2022-07-01)

Pharmacist-directed vancomycin therapeutic drug monitoring in pediatric patients: a collaborative-practice model
by: Kashif Hussain, et al.
Published: (2021-12-01)

Bayesian method application: Integrating mathematical modeling into clinical pharmacy through vancomycin therapeutic monitoring
by: Ashley Chen, et al.
Published: (2022-12-01)

Treatment of Periprosthetic Joint Infection with Intravenous Vancomycin: Do We Hit the Target?
by: Rasmus Haglund, et al.
Published: (2024-12-01)

Evaluation of Real-World Vancomycin Dosing and Attainment of Therapeutic Drug Monitoring Targets
by: Nicole Bradley, et al.
Published: (2023-06-01)

Therapeutic Drug Monitoring of Valproic Acid in Patients with
by: Mohsen Forooghipour, et al.
Published: (2009-09-01)

Evaluation of the Association between Trough and Area Under the Curve to Minimum Inhibitory Concentration Ratio (AUC24/MIC) of Vancomycin in Infected Patients with Methicillin Resistant Staphylococcus aureus (MRSA)
by: Ayda Esmaeili, et al.
Published: (2021-06-01)